UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2156-7
Program Prior Authorization/Medical Necessity
Medication Lucemyra® (lofexidine)
P&T Approval Date 11/2018, 11/2019, 1/2021, 2/2022, 2/2023, 2/2024, 4/2025
Effective Date 7/1/2025
1. Background:
Lucemyra is a central alpha-2 adrenergic agonist indicated for mitigation of opioid
withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
2. Coverage Criteriaa:
A. Lucemyra will be approved based on the following criteria:
1. All of the following:
a. For symptoms of abrupt opioid withdrawal. b
-AND-
b. Opioids have been discontinued. b
-AND-
c. One of the following:
(1) History of failure, contraindication, or intolerance to clonidine.
-OR-
(2) Lucemyra was initiated in the inpatient setting.
Authorization will be issued for 14 days of therapy. If Lucemyra was initiated in
the inpatient setting, the total course of therapy should not exceed 14 days.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b Plans sitused in Nevada are not subject to clinical criteria. Only step therapy may be required.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
© 2025 UnitedHealthcare Services Inc.
1
• Supply limits may also apply.
4. References:
1. Lucemyra [prescribing information]. Louisville, KY: WorldMeds, LLC; October 2023.
Gowing L, Farrell M, Ali R, White J. Alpha2-adrenergic agonists for the management of
opioid withdrawal. Cochrane Database of Systemic Reviews 2016, Issue 5.
Program Prior Authorization/Medical Necessity – Lucemyra
Change Control
Date Change
11/2018 New program.
11/2019 Annual review. No changes to criteria.
1/2021 Annual review. No changes to criteria.
2/2022 Annual review. Updated references.
2/2023 Annual review. No changes.
2/2024 Annual review. Nevada footnote added. Updated references.
4/2025 Annual review with no changes.
© 2025 UnitedHealthcare Services Inc.
2